WeVote
Log In

Bill

Bill

HB 2162

An Act amending the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, further providing for definitions and for license application.

2025-2026 Regular Session Introduced by Lisa Borowski and 24 co-sponsors

HB 2162 updates wholesale prescription drug distributor licensing in PA to clarify definitions and applications, aiming to boost compliance and support pharmaceutical innovation.

Referred to Institutional Sustainability & Innovation
0
WeVote Research Nonpartisan
Bill Summary · HB 2162

Overview

House Bill 2162 (2025-2026 Regular Session, Pennsylvania) proposes amendments to the Wholesale Prescription Drug Distributors License Act, enacted December 14, 1992. The measure focuses on clarifying definitions and updating the license application framework, with the broader aim of incentivizing pharmaceutical and biomedical innovation in Pennsylvania.

Purpose and Intent

  • Modernize and tighten the regulatory framework governing wholesale prescription drug distributors.
  • Improve clarity around key terms and licensing processes to support a robust, compliant distribution system.
  • Align licensing requirements with incentives or policies intended to foster pharmaceutical and biomedical innovation within the Commonwealth.

Key Provisions and Changes

  • Definitions: The bill would revise or add definitions relevant to wholesale prescription drug distributors and the licensing regime. While the exact definitional changes aren’t enumerated in the provided summary, the emphasis is on providing clearer, more precise terminology to support enforcement and compliance.
  • License Application: The bill would amend the license application provisions. This could include:
    • Updating application forms or required information.
    • Modifying eligibility criteria for distributors seeking a license.
    • Revising fee structures or timelines related to license issuance and renewal.
    • Enhancing compliance requirements for licensees (e.g., recordkeeping, reporting, or inspection provisions).
  • Administrative and Compliance Details: As part of amendments, there may be adjustments to administrative procedures (e.g., who reviews applications, appeal processes, or renewal cycles) and potential alignment with incentives for innovation in the pharmaceutical/biomedical sector.

Note: The exact textual changes (dollar figures, specific definitions, or step-by-step application requirements) are not provided in the summary you shared. The amendments were introduced as:
- House Amendments to Printers Number 2805 (A03371) and subsequently reported as amended (PN 3485).

Who Would Be Affected

  • Wholesale prescription drug distributors licensed under the 1992 Act (the Wholesale Prescription Drug Distributors License Act).
  • Applicants seeking new distributor licenses and current licensees undergoing renewal or compliance actions.
  • State regulatory agencies responsible for administering the license program (likely the Pennsylvania Department of Health or a related regulatory body, as historically involved in wholesale drug licensing).

Procedural and Timeline Aspects

  • Status: Re-committed to Rules on June 2, 2026 after initial action in the House Health Committee.
  • Committee Action: House Health Committee adopted amendments to HB 2162 (PN 2805 A03371) with a reported bill as amended. Committee votes showed strong approval (24-2 on amendment, 25-1 on the bill as amended).
  • Referral and Consideration Timeline:
    • Referred to the Health Committee on January 28, 2026.
    • Reported with amendments and first consideration on June 2, 2026.
    • Re-committed to Rules on the same day, indicating ongoing proceedings and potential for further motion or refinements.
  • Related Legislation: The statute being amended is the Wholesale Prescription Drug Distributors License Act (Act of December 14, 1992, P.L.1116, No.145). There is also reference to SB 1206 in the legislative context of similar amendments.

Potential Impact and Implications

  • Compliance Clarity: Easier for distributors to understand requirements, reducing ambiguity in definitions and licensing standards.
  • Innovation Incentives: The memo associated with the bill emphasizes incentivizing pharmaceutical and biomedical innovation, suggesting amendments may streamline processes or provide alignment with innovation goals (e.g., faster licensing for compliant distributors, or incentives linked to innovative supply chain practices).
  • Market Effects: Could affect licensing timelines, renewal cycles, and ongoing compliance costs for distributors, with potential downstream effects on drug distribution efficiency and drug availability in Pennsylvania.
  • Oversight and Enforcement: Likely adjustments to regulatory oversight mechanisms, inspections, or reporting obligations to ensure robust compliance while supporting innovation.

If you’d like, I can pull the exact text of the amendments (A03371 and PN 3485) to provide precise definitions, amended license application language, and any specific changes to application fees or timelines.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.